Post

New research · Infectious Disease
Hepatology communications · 23h
StudyHepatology communications · 2026

Safety and efficacy of libevitug in patients with chronic hepatitis B and D virus coinfection: A single-center, open-label, phase IIa trial in China.

Xinrui Wang, Xiumei Chi, Yingyu Zhang … Junqi Niu
Read paper
Infectious DiseaseStudy

Libevitug achieved virological response in most patients with hepatitis D.

Safety and efficacy of libevitug in patients with chronic hepatitis B and D virus coinfection: A single-center, open-label, phase IIa trial in China.

Xinrui Wang et al. · Hepatology communications · 2026
Background

Chronic HBV and HDV coinfection represents the most severe form of viral hepatitis.

Purpose

This study aimed to assess the safety and efficacy of libevitug (HH-003), a novel human monoclonal antibody targeting the PreS1 domain of the HBV large envelope protein, in patients with chronic HBV and HDV coinfection.

Methods

This single-center, open-label, proof-of-concept phase IIa clinical trial enrolled 9 participants who received i.v. infusion of 20 mg/kg libevitug every 2 weeks for 24 weeks, followed by a 24-week follow-up period.

n = 9 participants
77.8%
Results
77.8% of patients achieved a strong reduction in hepatitis D virus RNA.
n = 9 participants
More results

At week 24, 8 participants (88.9%) exhibited a reduction in HDV RNA ≥1 log10 from baseline, with 4 (44.4%) achieving undetectable levels.

Among the 5 participants with elevated baseline ALT, 3 (60.0%) achieved a combined virological and biochemical response (ALT normalization).

More results

At week 48, 6 participants (66.7%) maintained the virological response achieved at the end of treatment (week 24), with 3 (33.3%) maintaining undetectable HDV RNA levels.

Among the 7 participants with quantifiable HBV DNA at baseline, 2 (28.6%) achieved undetectable HBV DNA or ≥1 log10 reduction at week 24.

“
Conclusion

Libevitug demonstrated promising antiviral activity, achieving substantial HDV RNA reduction, a high rate of ALT normalization, and favorable safety and tolerability in participants with chronic HBV and HDV coinfection.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
100%
immediate bleeding control was achieved in all patients
Cohort Study
AHR, 1.09 [95% CI, 0.94-1.27]
similar risk of death for E. coli blood infections resistant vs susceptible to antibiotic
Study
90.5% (38/42)
most isolates were resistant to ampicillin and amoxicillin-sulbactam
Cohort Study
98%
nearly all refugee children received their missing childhood vaccines after arriving in Switzerland
Randomized Trial
33.3%
this percentage of participants experienced fatigue, the most common side effect
Cohort Study
182.1 per 100,000 population
this was the highest number of COVID-19 deaths per 100,000 food workers
Guideline
13
total guidance points for managing a chronic lung condition
Study
32-fold
removing the cfa gene made the bacteria much easier to kill with ampicillin